PLOD2 and central nervous system cancer: Consistent with the changes in expression, patients with higher expression of LDHA, MIF, NAMPT, PGK1, SAT1, and PLOD2, and lower expression of ALDOC, ABAT, ADCY2, GALNT13, and PDE8B showed poorer survival rates in all glioma samples (Supplementary Figure 4).